glp-1 vulva glp 1 🩺 “Ozempic Vulva” — social trend or clinical concern? Recent viral discussions have linked receptor agonists to changes in vulvar Understanding “Ozempic Vulva”: Why Vaginal

Most were similar to adverse effects observed in existing GLP-1 therapies

Anyone with a known allergy to glutathione or its ingredients

A larger clinical trial randomly assigned more than 500 patients with type 2 diabetes and symptomatic peripheral neuropathy to one of the following treatments: (i) 600 mg/day of intravenous lipoic acid for three weeks followed by 1,800 mg/day of oral lipoic acid for six months, (ii) 600 mg/day of intravenous lipoic acid for three weeks followed by oral placebo for six months, or (iii) intravenous placebo for three weeks followed by oral placebo for six months (76)

The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease